Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Author(s): Mahnoosh Rahimi and Sheldon Greenfield*

DOI: 10.2174/1875692119666220309120918

DownloadDownload PDF Flyer Cite As
A Systematic Review of Decipher Genomic Classifier Risk Scores for Prostate Cancer in African-Americans

Page: [7 - 20] Pages: 14

  • * (Excluding Mailing and Handling)

Abstract

Background: Prostate Cancer (PCa) is a non-cutaneous malignancy in men, and Decipher being a genomic test, has gained increasing attention in estimating the risk of developing a recurrence or metastatic PCa disease in patients. Therefore, this study is focused on evaluating the association of Decipher score risk with recurrence of prostate cancer patients based on their medical, genetic predictors, and demographics (e.g., races) by conducting a systematic review. Moreover, the study has also assessed whether Decipher score risk can be a good predictor for prostate patients’ metastasis and prostate cancer-specific mortality in men and clinical decision-making regarding patient treatment recommendations.

Methods: The research study has reviewed 74 research articles, and the systematic review results have been presented in the form of themes. The studies' review indicated that Decipher acts as a genomic metastasis signature to predict metastatic disease among patients and make better decisions about treating the disease. Moreover, this genomic test can also be used in conjunction with Magnetic Resonance Imaging (MRI) for identifying the lesions that may carry the biological potential for early metastases. Furthermore, this review also identified that treatment options for PCa might range from Adjuvant Radiation Treatment (ART) and Salvage Radiation Therapy (SRT) to Radical Prostatectomy (RP); however, the selection of treatment methodology depends upon the GC score and risk stratification.

Results: The results further suggested that the occurrence of PCa is two folds greater among African-Americans (AA) men as compared to non-AA men. Thus, the increasing incidence of PCa among AA and discrimination within AA's health and socio-economic conditions plays a significant role in treating AA. In this scenario, the Decipher test score plays an essential role in making treatment decisions.

Conclusion: To conclude, further trials are still required for validating the Decipher biomarkers, and scientists should enhance the decipher test ability to be run on a patient's blood samples instead of tumor tissue, which will help patients use decipher as a screening test at the asymptomatic level.

Keywords: Prostate cancer, decipher genomic classifier risk, metastasis, MRI, decipher test, biomarkers.

[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5-29.
[http://dx.doi.org/10.3322/caac.21254] [PMID: 25559415]
[3]
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013; 49(6): 1374-403.
[http://dx.doi.org/10.1016/j.ejca.2012.12.027] [PMID: 23485231]
[4]
Lee MC. Knowledge, barriers, and motivators related to cervical cancer screening among Korean-American women. A focus group approach. Cancer Nurs 2000; 23(3): 168-75.
[http://dx.doi.org/10.1097/00002820-200006000-00003] [PMID: 10851767]
[5]
Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life 2017; 10(1): 5-12.
[PMID: 28255369]
[6]
Karnes RJ, Choeurng V, Ross AE, et al. Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features. Eur Urol 2018; 73(2): 168-75.
[http://dx.doi.org/10.1016/j.eururo.2017.03.036] [PMID: 28400167]
[7]
Biosciences. Decipher biosciences. 2020. Available from: https://decipherbio.com/prostate/
[8]
Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw 2016; 14(1): 19-30.
[http://dx.doi.org/10.6004/jnccn.2016.0004] [PMID: 26733552]
[9]
Cooperberg MR, Erho N, Chan JM, et al. The diverse genomic landscape of clinically low-risk prostate cancer. Eur Urol 2018; 74(4): 444-52.
[http://dx.doi.org/10.1016/j.eururo.2018.05.014] [PMID: 29853306]
[10]
Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013; 8(6): e66855.
[http://dx.doi.org/10.1371/journal.pone.0066855] [PMID: 23826159]
[11]
Zhao SG, Chang SL, Spratt DE, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: A matched, retrospective analysis. Lancet Oncol 2016; 17(11): 1612-20.
[http://dx.doi.org/10.1016/S1470-2045(16)30491-0] [PMID: 27743920]
[12]
Zhao SG, Chang SL, Erho N, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol 2017; 3(12): 1663-72.
[http://dx.doi.org/10.1001/jamaoncol.2017.0751] [PMID: 28494073]
[13]
Gadzinski AJ, Cooperberg MR. Prostate cancer markers Cancer Treat Res 2018; 175: 55-86.
[http://dx.doi.org/10.1007/978-3-319-93339-9_3] [PMID: 30168117]
[14]
Nguyen PL, Haddad Z, Ross AE, et al. Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens. Eur Urol 2017; 72(5): 845-52.
[http://dx.doi.org/10.1016/j.eururo.2017.05.009] [PMID: 28528811]
[15]
Ross AE, Feng FY, Ghadessi M, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis 2014; 17(1): 64-9.
[http://dx.doi.org/10.1038/pcan.2013.49] [PMID: 24145624]
[16]
Klein EA, Haddad Z, Yousefi K, et al. Decipher genomic classifier measured on prostate biopsy predicts metastasis risk. Urology 2016; 90: 148-52.
[http://dx.doi.org/10.1016/j.urology.2016.01.012] [PMID: 26809071]
[17]
Den RB, Yousefi K, Trabulsi EJ, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 2015; 33(8): 944-51.
[http://dx.doi.org/10.1200/JCO.2014.59.0026] [PMID: 25667284]
[18]
Klein EA, Yousefi K, Haddad Z, et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 2015; 67(4): 778-86.
[http://dx.doi.org/10.1016/j.eururo.2014.10.036] [PMID: 25466945]
[19]
Alshalalfa M, Crisan A, Vergara IA, et al. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 2015; 116(4): 556-67.
[http://dx.doi.org/10.1111/bju.13013] [PMID: 25762434]
[20]
Van den Broeck T, Moris L, Gevaert T, et al. Validation of the decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery. Eur Urol Oncol 2019; 2(5): 589-96.
[http://dx.doi.org/10.1016/j.euo.2018.12.007] [PMID: 31411980]
[21]
Knudsen BS, Kim HL, Erho N, et al. Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens. J Mol Diagn 2016; 18(3): 395-406.
[http://dx.doi.org/10.1016/j.jmoldx.2015.12.006] [PMID: 26945428]
[22]
Spratt DE, Zhang J, Santiago-Jiménez M, et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J Clin Oncol 2018; 36(6): 581-90.
[http://dx.doi.org/10.1200/JCO.2017.74.2940] [PMID: 29185869]
[23]
Nguyen PL, Martin NE, Choeurng V, et al. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis 2017; 20(2): 186-92.
[http://dx.doi.org/10.1038/pcan.2016.58] [PMID: 28117383]
[24]
Badani KK, Thompson DJ, Brown G, et al. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int 2015; 115(3): 419-29.
[http://dx.doi.org/10.1111/bju.12789] [PMID: 24784420]
[25]
Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2015; 67(2): 326-33.
[http://dx.doi.org/10.1016/j.eururo.2014.05.039] [PMID: 24998118]
[26]
Ross AE, Johnson MH, Yousefi K, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol 2016; 69(1): 157-65.
[http://dx.doi.org/10.1016/j.eururo.2015.05.042] [PMID: 26058959]
[27]
Den RB, Santiago-Jimenez M, Alter J, et al. Decipher correlation patterns post prostatectomy: Initial experience from 2 342 prospective patients. Prostate Cancer Prostatic Dis 2016; 19(4): 374-9.
[http://dx.doi.org/10.1038/pcan.2016.38] [PMID: 27574020]
[28]
Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008; 53(5): 950-9.
[http://dx.doi.org/10.1016/j.eururo.2007.10.008] [PMID: 17950521]
[29]
Ahmadi H, Daneshmand S. Androgen deprivation therapy: Evidence-based management of side effects. BJU Int 2013; 111(4): 543-8.
[http://dx.doi.org/10.1111/j.1464-410X.2012.11774.x] [PMID: 23351025]
[30]
Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16(4): 579-84.
[http://dx.doi.org/10.1093/annonc/mdi122] [PMID: 15734776]
[31]
Nakagawa T, Kollmeyer TM, Morlan BW, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 2008; 3(5): e2318.
[http://dx.doi.org/10.1371/journal.pone.0002318] [PMID: 18846227]
[32]
Spratt DE, Dai DLY, Den RB, et al. Performance of a prostate cancer genomic classifier in predicting metastasis in men with prostate-specific antigen persistence postprostatectomy. Eur Urol 2018; 74(1): 107-14.
[http://dx.doi.org/10.1016/j.eururo.2017.11.024] [PMID: 29233664]
[33]
Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med 2020; 382(10): 917-28.
[http://dx.doi.org/10.1056/NEJMoa1910038] [PMID: 32130814]
[34]
Borofsky S, George AK, Gaur S, et al. What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. Radiology 2018; 286(1): 186-95.
[http://dx.doi.org/10.1148/radiol.2017152877] [PMID: 29053402]
[35]
Johnson DC, Raman SS, Mirak SA, et al. Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol 2019; 75(5): 712-20.
[http://dx.doi.org/10.1016/j.eururo.2018.11.031] [PMID: 30509763]
[36]
Hectors SJ, Cherny M, Yadav KK, et al. Radiomics features measured with multiparametric magnetic resonance imaging predict prostate cancer aggressiveness. J Urol 2019; 202(3): 498-505.
[http://dx.doi.org/10.1097/JU.0000000000000272] [PMID: 30958743]
[37]
Stoyanova R, Pollack A, Takhar M, et al. Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget 2016; 7(33): 53362-76.
[http://dx.doi.org/10.18632/oncotarget.10523] [PMID: 27438142]
[38]
Purysko AS, Magi-Galluzzi C, Mian OY, et al. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: Preliminary findings. Eur Radiol 2019; 29(9): 4861-70.
[http://dx.doi.org/10.1007/s00330-019-06114-x] [PMID: 30847589]
[39]
Ross AE, Den RB, Yousefi K, et al. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis 2016; 19(3): 277-82.
[http://dx.doi.org/10.1038/pcan.2016.15] [PMID: 27136742]
[40]
Gore JL, du Plessis M, Santiago-Jiménez M, et al. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer 2017; 123(15): 2850-9.
[http://dx.doi.org/10.1002/cncr.30665] [PMID: 28422278]
[41]
Patrikidou A, Loriot Y, Eymard JC, et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348-52.
[http://dx.doi.org/10.1038/pcan.2014.35] [PMID: 25311767]
[42]
Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 2012; 80(5): 1075-9.
[http://dx.doi.org/10.1016/j.urology.2012.07.040] [PMID: 22995570]
[43]
Sundi D, Tosoian JJ, Nyame YA, et al. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer 2019; 125(3): 391-7.
[http://dx.doi.org/10.1002/cncr.31833] [PMID: 30423193]
[44]
Ross A, Johnson MH, Yousefi K, et al. Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort. J Clin Oncol 2015; 33(15)(Suppl.): 5059-9.
[http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5059]
[45]
Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 2015; 314(1): 80-2.
[http://dx.doi.org/10.1001/jama.2015.6036] [PMID: 26151271]
[46]
Nguyen PL, Shin H, Yousefi K, et al. Impact of a genomic classifier of metastatic risk on postprostatectomy treatment recommendations by radiation oncologists and urologists. Urology 2015; 86(1): 35-40.
[http://dx.doi.org/10.1016/j.urology.2015.04.004] [PMID: 26142578]
[47]
Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17(5): 479-505.
[http://dx.doi.org/10.6004/jnccn.2019.0023] [PMID: 31085757]
[48]
Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. CaPSURE. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003; 170(6 Pt 2): S21-5.
[http://dx.doi.org/10.1097/01.ju.0000095025.03331.c6] [PMID: 14610406]
[49]
Uchio E, Meyskens FL, Wang PH. Deciphering the effect of metformin on prostate cancer risk by ethnicity. Cancer Prev Res (Phila) 2016; 9(10): 777-8.
[http://dx.doi.org/10.1158/1940-6207.CAPR-16-0173] [PMID: 27432345]
[50]
Zeigler-Johnson CM, Walker AH, Mancke B, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002; 54(1): 13-21.
[http://dx.doi.org/10.1159/000066695] [PMID: 12446983]
[51]
Powell IJ, Bollig-Fischer A. Minireview: The molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol 2013; 27(6): 879-91.
[http://dx.doi.org/10.1210/me.2013-1039] [PMID: 23608645]
[52]
Mahal BA, Ziehr DR, Aizer AA, et al. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol 2014; 32(8): 1285-91.
[http://dx.doi.org/10.1016/j.urolonc.2014.04.014] [PMID: 24846344]
[53]
Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer-specific mortality across gleason scores in black vs nonblack men. JAMA 2018; 320(23): 2479-81.
[http://dx.doi.org/10.1001/jama.2018.11716] [PMID: 30561471]
[54]
Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults: The Atherosclerosis Risk in Communities Study. JAMA 2000; 283(17): 2253-9.
[http://dx.doi.org/10.1001/jama.283.17.2253] [PMID: 10807384]
[55]
Dess RT, Hartman HE, Mahal BA, et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 2019; 5(7): 975-83.
[http://dx.doi.org/10.1001/jamaoncol.2019.0826] [PMID: 31120534]
[56]
Yamoah K, Johnson MH, Choeurng V, et al. Novel biomarker signature that may predict aggressive disease in african american men with prostate cancer. J Clin Oncol 2015; 33(25): 2789-96.
[http://dx.doi.org/10.1200/JCO.2014.59.8912] [PMID: 26195723]
[57]
Erho N, Buerki C, Triche TJ, Davicioni E, Vergara IA. Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer. J Oncol 2012; 2012: 541353.
[http://dx.doi.org/10.1155/2012/541353] [PMID: 22956952]
[58]
Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009; 101(14): 984-92.
[http://dx.doi.org/10.1093/jnci/djp175] [PMID: 19584328]
[59]
Kerns SL, Ostrer H, Stock R, et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78(5): 1292-300.
[http://dx.doi.org/10.1016/j.ijrobp.2010.07.036] [PMID: 20932654]
[60]
Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368(5): 436-45.
[http://dx.doi.org/10.1056/NEJMoa1209978] [PMID: 23363497]
[61]
Pardo Y, Guedea F, Aguiló F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010; 28(31): 4687-96.
[http://dx.doi.org/10.1200/JCO.2009.25.3245] [PMID: 20921463]
[62]
Mahal BA, Chen MH, Bennett CL, et al. The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis 2015; 18(1): 38-42.
[http://dx.doi.org/10.1038/pcan.2014.42] [PMID: 25348256]
[63]
Halbert CH, Weathers B, Delmoor E, et al. Racial differences in medical mistrust among men diagnosed with prostate cancer. Cancer 2009; 115(11): 2553-61.
[http://dx.doi.org/10.1002/cncr.24249] [PMID: 19296516]
[64]
Moore AD, Hamilton JB, Knafl GJ, et al. The influence of mistrust, racism, religious participation, and access to care on patient satisfaction for African American men: The North Carolina-Louisiana Prostate Cancer Project. J Natl Med Assoc 2013; 105(1): 59-68.
[http://dx.doi.org/10.1016/S0027-9684(15)30086-9] [PMID: 23862297]
[65]
Howard LE, Zhang J, Fishbane N, et al. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer Prostatic Dis 2020; 23(3): 419-28.
[PMID: 31844180]
[66]
Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: A review. JAMA 2017; 317(24): 2532-42.
[http://dx.doi.org/10.1001/jama.2017.7248] [PMID: 28655021]
[67]
Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014; 66(3): 550-60.
[http://dx.doi.org/10.1016/j.eururo.2014.05.004] [PMID: 24836057]
[68]
Blume-Jensen P, Berman DM, Rimm DL, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res 2015; 21(11): 2591-600.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2603] [PMID: 25733599]
[69]
Shore N, Concepcion R, Saltzstein D, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin 2014; 30(4): 547-53.
[http://dx.doi.org/10.1185/03007995.2013.873398] [PMID: 24320750]
[70]
Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: Results from an ongoing registry. Curr Med Res Opin 2014; 30(6): 1025-31.
[http://dx.doi.org/10.1185/03007995.2014.899208] [PMID: 24576172]
[71]
Apolo AB, Riches J, Schöder H, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010; 28(25): 3973-8.
[http://dx.doi.org/10.1200/JCO.2010.28.7052] [PMID: 20679618]
[72]
Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013; 31(11): 1428-34.
[http://dx.doi.org/10.1200/JCO.2012.46.4396] [PMID: 23460710]
[73]
Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular biomarkers: Opportunities and challenges. Int J Mol Sci 2019; 20(8): E1813.
[http://dx.doi.org/10.3390/ijms20081813] [PMID: 31013716]
[74]
Den RB, Feng FY, Showalter TN, et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2014; 89(5): 1038-46.
[http://dx.doi.org/10.1016/j.ijrobp.2014.04.052] [PMID: 25035207]